HUE067276T2 - Obicetrapib demenciák kezelésére - Google Patents
Obicetrapib demenciák kezeléséreInfo
- Publication number
- HUE067276T2 HUE067276T2 HUE22715162A HUE22715162A HUE067276T2 HU E067276 T2 HUE067276 T2 HU E067276T2 HU E22715162 A HUE22715162 A HU E22715162A HU E22715162 A HUE22715162 A HU E22715162A HU E067276 T2 HUE067276 T2 HU E067276T2
- Authority
- HU
- Hungary
- Prior art keywords
- obicetrapib
- dementias
- treatment
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 title 1
- 229950004285 obicetrapib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163157586P | 2021-03-05 | 2021-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE067276T2 true HUE067276T2 (hu) | 2024-10-28 |
Family
ID=81327869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE22715162A HUE067276T2 (hu) | 2021-03-05 | 2022-03-04 | Obicetrapib demenciák kezelésére |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP4125911B1 (hu) |
| JP (1) | JP2024513155A (hu) |
| KR (1) | KR20230159457A (hu) |
| CN (1) | CN117529319A (hu) |
| AU (1) | AU2022231417A1 (hu) |
| BR (1) | BR112023017999A2 (hu) |
| CA (1) | CA3212483A1 (hu) |
| DK (1) | DK4125911T3 (hu) |
| ES (1) | ES2988112T3 (hu) |
| FI (1) | FI4125911T3 (hu) |
| HU (1) | HUE067276T2 (hu) |
| IL (1) | IL305576B2 (hu) |
| LT (1) | LT4125911T (hu) |
| MX (1) | MX2023010211A (hu) |
| PL (1) | PL4125911T3 (hu) |
| PT (1) | PT4125911T (hu) |
| SI (1) | SI4125911T1 (hu) |
| WO (1) | WO2022185120A1 (hu) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202409008A (zh) | 2022-07-05 | 2024-03-01 | 荷蘭商新阿姆斯特丹製藥公司 | 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| EP2281824A1 (en) * | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| HUE042932T2 (hu) * | 2014-02-05 | 2019-07-29 | Dezima Pharma B V | Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra |
| LT3180314T (lt) | 2014-08-12 | 2022-11-10 | Newamsterdam Pharma B.V. | Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas |
-
2022
- 2022-03-04 CA CA3212483A patent/CA3212483A1/en active Pending
- 2022-03-04 HU HUE22715162A patent/HUE067276T2/hu unknown
- 2022-03-04 IL IL305576A patent/IL305576B2/en unknown
- 2022-03-04 KR KR1020237033972A patent/KR20230159457A/ko active Pending
- 2022-03-04 EP EP22715162.8A patent/EP4125911B1/en active Active
- 2022-03-04 JP JP2023553588A patent/JP2024513155A/ja active Pending
- 2022-03-04 FI FIEP22715162.8T patent/FI4125911T3/fi active
- 2022-03-04 EP EP24150094.1A patent/EP4368250A3/en active Pending
- 2022-03-04 CN CN202280025877.9A patent/CN117529319A/zh active Pending
- 2022-03-04 WO PCT/IB2022/000098 patent/WO2022185120A1/en active Application Filing
- 2022-03-04 LT LTEPPCT/IB2022/000098T patent/LT4125911T/lt unknown
- 2022-03-04 AU AU2022231417A patent/AU2022231417A1/en active Pending
- 2022-03-04 PL PL22715162.8T patent/PL4125911T3/pl unknown
- 2022-03-04 MX MX2023010211A patent/MX2023010211A/es unknown
- 2022-03-04 DK DK22715162.8T patent/DK4125911T3/da active
- 2022-03-04 ES ES22715162T patent/ES2988112T3/es active Active
- 2022-03-04 SI SI202230044T patent/SI4125911T1/sl unknown
- 2022-03-04 BR BR112023017999A patent/BR112023017999A2/pt unknown
- 2022-03-04 PT PT227151628T patent/PT4125911T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4368250A3 (en) | 2024-08-14 |
| CN117529319A (zh) | 2024-02-06 |
| PT4125911T (pt) | 2024-07-12 |
| BR112023017999A2 (pt) | 2023-11-14 |
| EP4368250A2 (en) | 2024-05-15 |
| IL305576B1 (en) | 2024-09-01 |
| AU2022231417A1 (en) | 2023-10-19 |
| FI4125911T3 (fi) | 2024-07-22 |
| PL4125911T3 (pl) | 2024-11-04 |
| KR20230159457A (ko) | 2023-11-21 |
| EP4125911A1 (en) | 2023-02-08 |
| JP2024513155A (ja) | 2024-03-22 |
| WO2022185120A1 (en) | 2022-09-09 |
| IL305576A (en) | 2023-10-01 |
| DK4125911T3 (da) | 2024-07-15 |
| EP4125911B1 (en) | 2024-04-24 |
| ES2988112T3 (es) | 2024-11-19 |
| CA3212483A1 (en) | 2022-09-09 |
| IL305576B2 (en) | 2025-01-01 |
| LT4125911T (lt) | 2024-08-12 |
| MX2023010211A (es) | 2023-11-22 |
| SI4125911T1 (sl) | 2024-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288523A (en) | Compounds for the treatment of pd-l1 diseases | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL291362A (en) | Syngap1 brain degeneration treatment | |
| IL290756A (en) | Treatment of azoles | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| PL3743064T3 (pl) | Leczenie proteinurii | |
| IL287250A (en) | treatment method | |
| PL4125911T3 (pl) | Obicetrapib do leczenia otępień | |
| SG11202105877YA (en) | Method of treatment | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB201916428D0 (en) | Treatment of hydro-carbon-contaminated materials | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| GB2595513B (en) | Treatment of infections | |
| GB201918853D0 (en) | Methods of treatment | |
| ZA202003088B (en) | Treatment of tuberculosis | |
| GB202101251D0 (en) | Treatment of conditions | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202118006D0 (en) | Methods of treatment | |
| GB202118007D0 (en) | Methods of treatment | |
| IL290983A (en) | Treatment methods | |
| GB202108245D0 (en) | Methods of treatment | |
| GB202108242D0 (en) | Methods of treatment | |
| GB201917253D0 (en) | Treatment of conditions | |
| IL310241A (en) | Lupus treatment | |
| GB202005874D0 (en) | Methods of treatment |